Oligometastatic versus polymetastatic colon cancer: functional and genomic determinants of divergent metastatic trajectories

Abstract

Aim: The aim of this study is to investigate the molecular and functional features underlying the clinical heterogeneity between oligometastatic (OM) and polymetastatic (PM) colon cancer.

Methods: We performed a genotype-phenotype analysis in a homogeneous cohort of 127 patients with metastatic colon cancer (mCC) profiled using the same next-generation sequencing platform (TruSight Oncology^® 500). OM disease was defined as the presence of one to three metastatic lesions per involved organ, involving no more than two organs overall, with all lesions measuring < 70 mm in maximum diameter and no single lesion > 25 mm. Molecular alterations, microsatellite instability (MSI), tumor mutational burden (TMB), and overall survival (OS) were analyzed. Gene Ontology (GO) enrichment and Phenolyzer network analyses were applied to explore functional differences between prognostically distinct molecular subgroups.

Results: OM patients showed a striking survival advantage compared with PM patients [median OS not reached versus 29 months; hazard ratio (HR): 0.20, P < 0.0001], validating the clinical distinction between the two phenotypes. PM disease was significantly enriched for RAS mutations, whereas OM disease was associated with MSI-high status and elevated TMB. Canonical driver alterations were largely shared between groups, and Phenolyzer analysis revealed similar core oncogenic networks centered on adenomatous polyposis coli APC), tumor protein p53 TP53), and epidermal growth factor receptor EGFR). In contrast, GO analysis demonstrated selective enrichment in PM tumors for molecular functions related to ATP binding, nucleotide binding, and protein kinase activity, consistent with enhanced bioenergetic demand and signaling intensity.

Conclusions: These findings support refined biological stratification of mCC and the exploration of personalized, metastasis-directed strategies, potentially incorporating immunological modulation in OM disease.

Keywords

metastatic colon cancer / oligometastatic disease / tumor mutational burden / gene ontology / genotype-phenotype correlation

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49.

[2] Capuozzo M, Picone C, Sabbatino F, Santorsola M, Caraglia F, Iervolino D, et al. Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers. Cancers (Basel). 2025; 17: 3438.

[3] Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al.; ESMO Guidelines Committee. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34: 10-32.

[4] Ottaiano A, Santorsola M, Circelli L, Trotta AM, Izzo F, Perri F, et al. Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives. Cancers (Basel). 2023; 15: 1827.

[5] Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020; 148: 157-66.

[6] Sonkin D, Thomas A, Teicher BA. Cancer treatments: Past, present, and future. Cancer Genet. 2024; 286-287: 18-24.

[7] Ottaiano A, Nasti G, Santorsola M, Altieri V, Di Fruscio G, Circelli L, et al. KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer. Front Oncol. 2021; 11: 632962.

[8] Ottaiano A, de Vera d’Aragona RP, Trotta AM, Santorsola M, Napolitano M, Scognamiglio G, et al. Characterization of KRAS Mutational Regression in Oligometastatic Patients. Front Immunol. 2022; 13: 898561.

[9] Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol. 2020; 17: 675-86.

[10] Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011; 8: 378-82.

[11] Ray SK, Mukherjee S. Exploring replication stress and cellular senescence as key targets in novel cancer therapies. Cancer Genet. 2025; 298-299: 78-87.

[12] Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27: 1386-422.

[13] Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015; 33: 90-9.

[14] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-47.

[15] Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9: 34.

[16] Cortes-Ciriano I, Lee S, Park WY, Kim TM, Park PJ. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017; 8: 15180.

[17] Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25: 1754-60.

[18] Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017; 19: 4-23.

[19] Li MM, Cottrell CE, Pullambhatla M, Roy S, Temple-Smolkin RL, Turner SA, et al. Assessments of Somatic Variant Classification Using the Association for Molecular Pathology/American Society of Clinical Oncology/College of American Pathologists Guidelines: A Report from the Association for Molecular Pathology. J Mol Diagn. 2023; 25: 69-86.

[20] Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022; 7: 100336.

[21] Yang H, Robinson PN, Wang K. Phenolyzer: phenotype-based prioritization of candidate genes for human diseases. Nat Methods. 2015; 12: 841-3.

[22] Xu T, Li J, Wang Z, Zhang X, Zhou J, Lu Z, et al. Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer. Cancer Med. 2023; 12: 10473-84.

[23] Wilbur HC, Le DT, Agarwal P. Immunotherapy of MSI Cancer: Facts and Hopes. Clin Cancer Res. 2024; 30: 1438-47.

[24] Wang Q, Yu M, Zhang S. The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies. Front Immunol. 2025; 15: 1440830.

[25] Zhang J, Xu Y, Han X, Gao Y, Wei Z, Sun X. Galectin-9 promotes colon cancer development by polarizing macrophages toward the M2 phenotype. Cancer Genet. 2025; 298-299: 141-50.

[26] Jahangiri L. The impact of extracellular vesicles on breast cancer metastasis and therapeutics: genetic considerations. Cancer Genet. 2025; 298-299: 1-9.

[27] Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008; 8: 193-204.

[28] de Almeida LC, Calil FA, Machado-Neto JA, Costa-Lotufo LV. DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy. Cancer Genet. 2021; 252-253: 6-24.

[29] Chen H, Chong W, Wu Q, Yao Y, Mao M, Wang X. Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. Front Immunol. 2019; 10: 1113.

[30] He Z, Feng W, Wang Y, Shi L, Gong Y, Shi Y, et al. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. Transl Lung Cancer Res. 2023; 12: 510-29.

[31] Tan S, Chen Y, Chen Y, Liu S, Yang C, Mi Y, et al. HOXC8-activated TRIM22/NF-κB pathway promotes stemness in colorectal cancer. Cancer Lett. 2026; 638: 218156.

[32] Liu H, Guo Z, Wang P. Genetic expression in cancer research: Challenges and complexity. Gene Rep. 2024; 37: 102042.

[33] Liu H, Li Y, Karsidag M, Tu T, Wang P. Technical and Biological Biases in Bulk Transcriptomic Data Mining for Cancer Research. J Cancer. 2025; 16: 34-43.

[34] Liu H. A prospective for the potential effect of local anesthetics on stem-like cells in colon cancer. Biomed J Sci Tech Res. 2020; 25.